There were a lot of moments in 2022 that left us scratching our heads. In this episode, we’ll recap biotech’s top blunders, boondoggles, gaffes and missteps in our "Rotten Tomatoes" report—plus, we highlight two ripened tomatoes that gave us hope.
Also in this episode, we cover the week's biggest headlines including drug approvals late in the last stretch of 2022, Moderna's first buy and why Biogen and the FDA are in hot water.
To learn more about topics in this episode:
- Fierce Biotech's Rotten Tomatoes of 2022
- Roche gets FDA nod for Lunsumio, offering convenient option to gene therapies in follicular lymphoma
- After overcoming vial issue, Gilead wins FDA approval for long-acting HIV injectable Sunlenca
- After FDA's Ukoniq pull, TG Therapeutics wins commercial mulligan with Briumvi to enter crowded MS arena
- Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report
- Moderna makes its first-ever acquisition, buying Japanese DNA manufacturer OriCiro for $85M
- Moderna CEO says mpox vaccine is 'fantastic.' It may never see the market
- GE HealthCare completes spinout into 'more focused, more agile' standalone company
- We're looking for the fiercest companies for Fierce Medtech's 2022 Fierce 15
- Fierce JPM Week
"The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.